Background: The mutated BRAF V600E protein has been specifically detected in papillary
thyroid carcinomas (PTCs) using immunohistochemical (IHC) analysis. The clonal origin of …

Context: The homogeneous distribution of BRAF V600E in papillary thyroid carcinoma (PTC)
has been called into question by recent reports. These studies claim that BRAF V600E is …

Objective The somatic point mutation in the BRAF gene, which results in a valine-to-
glutamate substitution at residue 600 (BRAFV600E), is an ideal hallmark of papillary thyroid …

A BRAF somatic mutation at residue 600 of the BRAF protein (BRAFV600E) is highly
prevalent in papillary thyroid carcinomas (PTC). This mutation occurs in approximately …

Background: Papillary thyroid carcinoma (PTC) is the most common malignant tumor of the
thyroid gland, accounting for 74–80% of all thyroid cancers. The 1799T> A transversion is an …

Background: Approximately 45% of papillary thyroid carcinomas harbor BRAF p. V600E
mutations and current practice algorithms endorse molecular testing for BRAF p. V600E. We …

Summary Purpose BRAF V600E mutation represents the most common oncogenic event in
sporadic papillary thyroid cancer (PTC). There are, however, significant discrepancies …

Abstract Context: Although the BRAF V600E mutant can initiate the formation of papillary
thyroid cancer (PTC), it is unclear whether it is required to maintain cell proliferation …

Somatic mutations in BRAF, especially BRAFV600E, are frequently identified in papillary
thyroid cancer (PTC) tumors. It has been established that expression levels of numbers of …

Context: Because very few studies have examined the correlation between BRAF mutations
and clinicopathological features of papillary thyroid carcinoma (PTC), we analyzed here a …